Immune Checkpoint Inhibitor Metastatic NSCLC: Combination Strategies

home / investigator-perspectives / immune-checkpoint-inhibitor-metastatic-nsclc-combination-strategies

Edward B. Garon, MD, MS, provides his expert perspective on immune checkpoint inhibition in metastatic non-small cell lung cancer (mNSCLC) and evaluates the currently available immunotherapy combinations.

Common Adverse Events to Immunotherapies in mNSCLC

EP. 1: Common Adverse Events to Immunotherapies in mNSCLC

Edward B. Garon, MD, MS
November 15th 2022

A lung cancer expert describes the common adverse events he sees with immunotherapy in mNSCLC, and the available management strategies.

Watch

Biomarker Testing for Targetable Mutations in Non-Small Cell Lung Cancer (NSCLC)

EP. 2: Biomarker Testing for Targetable Mutations in Non-Small Cell Lung Cancer (NSCLC)

Edward B. Garon, MD, MS
November 15th 2022

Edward B. Garon, MD, MS, shares his biomarker testing protocols for patients with NSCLC and highlights the most important biomarkers for guiding therapy.

Watch

Rationale for Treatment of mNSCLC with Immune Checkpoint Inhibitors

EP. 3: Rationale for Treatment of mNSCLC with Immune Checkpoint Inhibitors

Edward B. Garon, MD, MS
November 15th 2022

Dr Edward B. Garon explains the rationale for treating patients with mNSCLC with a frontline combination of chemotherapy and immune checkpoint inhibitors.

Watch

Clinical Implications of Recent Data and the Future of mNSCLC

EP. 4: Clinical Implications of Recent Data and the Future of mNSCLC

Edward B. Garon, MD, MS
November 15th 2022

Closing the program, Edward B. Garon, MD, MS, shares his view on the implications of recent mNSCLC data in clinical practice, and the unmet needs the field must focus on in the future.

Watch

Updated Analysis of the POSEIDON Trial in mNSCLC from World Lung 2022

EP. 5: Updated Analysis of the POSEIDON Trial in mNSCLC from World Lung 2022

Edward B. Garon, MD, MS
November 15th 2022

Dr Garon continues with an explanation of the updated analysis of the POSEIDON trial presented at the 2022 World Conference on Lung Cancer.

Watch

Chemoimmunotherapy in mNSCLC: Design and Outcomes of the POSEIDON Trial

EP. 6: Chemoimmunotherapy in mNSCLC: Design and Outcomes of the POSEIDON Trial

Edward B. Garon, MD, MS
November 15th 2022

A key opinion leader reviews the study design and efficacy and safety outcomes of the POSEIDON trial investigating durvalumab + tremelimumab + chemotherapy for treatment of mNSCLC.

Watch